480 related articles for article (PubMed ID: 35121991)
1. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer.
Liu B; Hu X; Feng K; Gao R; Xue Z; Zhang S; Zhang Y; Corse E; Hu Y; Han W; Zhang Z
Nat Cancer; 2022 Jan; 3(1):108-121. PubMed ID: 35121991
[TBL] [Abstract][Full Text] [Related]
2. Clonal replacement of tumor-specific T cells following PD-1 blockade.
Yost KE; Satpathy AT; Wells DK; Qi Y; Wang C; Kageyama R; McNamara KL; Granja JM; Sarin KY; Brown RA; Gupta RK; Curtis C; Bucktrout SL; Davis MM; Chang ALS; Chang HY
Nat Med; 2019 Aug; 25(8):1251-1259. PubMed ID: 31359002
[TBL] [Abstract][Full Text] [Related]
3. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.
Zhang J; Ji Z; Caushi JX; El Asmar M; Anagnostou V; Cottrell TR; Chan HY; Suri P; Guo H; Merghoub T; Chaft JE; Reuss JE; Tam AJ; Blosser RL; Abu-Akeel M; Sidhom JW; Zhao N; Ha JS; Jones DR; Marrone KA; Naidoo J; Gabrielson E; Taube JM; Velculescu VE; Brahmer JR; Housseau F; Hellmann MD; Forde PM; Pardoll DM; Ji H; Smith KN
Clin Cancer Res; 2020 Mar; 26(6):1327-1337. PubMed ID: 31754049
[TBL] [Abstract][Full Text] [Related]
4. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade-unresponsive human tumor-infiltrating CD8
Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC
Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901
[TBL] [Abstract][Full Text] [Related]
7. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients.
Naidus E; Bouquet J; Oh DY; Looney TJ; Yang H; Fong L; Standifer NE; Zhang L
Cancer Immunol Immunother; 2021 Jul; 70(7):2095-2102. PubMed ID: 33420629
[TBL] [Abstract][Full Text] [Related]
8. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
9. Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer.
Someya M; Tokita S; Kanaseki T; Kitagawa M; Hasegawa T; Tsuchiya T; Fukushima Y; Gocho T; Kozuka Y; Mafune S; Ikeuchi Y; Takahashi M; Moniwa K; Matsuo K; Hasegawa T; Torigoe T; Sakata KI
Cancer Sci; 2022 Dec; 113(12):4394-4400. PubMed ID: 36069051
[TBL] [Abstract][Full Text] [Related]
10. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Kamphorst AO; Pillai RN; Yang S; Nasti TH; Akondy RS; Wieland A; Sica GL; Yu K; Koenig L; Patel NT; Behera M; Wu H; McCausland M; Chen Z; Zhang C; Khuri FR; Owonikoko TK; Ahmed R; Ramalingam SS
Proc Natl Acad Sci U S A; 2017 May; 114(19):4993-4998. PubMed ID: 28446615
[TBL] [Abstract][Full Text] [Related]
11. IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137
Ugolini A; Zizzari IG; Ceccarelli F; Botticelli A; Colasanti T; Strigari L; Rughetti A; Rahimi H; Conti F; Valesini G; Marchetti P; Nuti M
EBioMedicine; 2020 Dec; 62():103098. PubMed ID: 33166793
[TBL] [Abstract][Full Text] [Related]
12. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
13. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
14. TCF1
Koh J; Kim S; Woo YD; Song SG; Yim J; Han B; Lim S; Ahn HK; Mun S; Kim JS; Keam B; Kim YA; Lee SH; Jeon YK; Chung DH
Eur J Cancer; 2022 Oct; 174():10-20. PubMed ID: 35970031
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Caushi JX; Zhang J; Ji Z; Vaghasia A; Zhang B; Hsiue EH; Mog BJ; Hou W; Justesen S; Blosser R; Tam A; Anagnostou V; Cottrell TR; Guo H; Chan HY; Singh D; Thapa S; Dykema AG; Burman P; Choudhury B; Aparicio L; Cheung LS; Lanis M; Belcaid Z; El Asmar M; Illei PB; Wang R; Meyers J; Schuebel K; Gupta A; Skaist A; Wheelan S; Naidoo J; Marrone KA; Brock M; Ha J; Bush EL; Park BJ; Bott M; Jones DR; Reuss JE; Velculescu VE; Chaft JE; Kinzler KW; Zhou S; Vogelstein B; Taube JM; Hellmann MD; Brahmer JR; Merghoub T; Forde PM; Yegnasubramanian S; Ji H; Pardoll DM; Smith KN
Nature; 2021 Aug; 596(7870):126-132. PubMed ID: 34290408
[TBL] [Abstract][Full Text] [Related]
16. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
17. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer.
Qiao M; Zhou F; Liu X; Jiang T; Wang H; Jia Y; Li X; Zhao C; Cheng L; Chen X; Ren S; Liu H; Zhou C
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543373
[TBL] [Abstract][Full Text] [Related]
19. T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection.
Chang YM; Wieland A; Li ZR; Im SJ; McGuire DJ; Kissick HT; Antia R; Ahmed R
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759317
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy.
Shi L; Lu J; Zhong D; Song M; Liu J; You W; Li WH; Lin L; Shi D; Chen Y
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
